1Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001, 34:1225-1241
2Bock CT, Tillmann H, Torresi J, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology. 2002, 122:264-273.
3Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviralresistant human hepatitis B virus mutations in the polymerase region.Hepatology 2001, 33 : 751-757.
4Torresi J, Earnest-Silveira L, Deliyarmis G, et al. Reduced antigeriicity of the hepatitis B virus HBsAg protein arising as a consequence of sequence changes in the overlapping polymerase gene that are selected by lamivudine therapy. Virology, 2002, 293:305-313.
5Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology. 2003, 125:292-297.
6Bozdayi AM, Uzunalimoglu O, Turkyilmaz AR, et al. YSDD: a novel mutation in HBV DNA polyrnerase confers clinical resistance to lamivudine. J Viral Hepatitis. 2003, 10:256-265.
同被引文献149
1Jing You Lin Zhuang Bao Zhang Tang Wei Bo Yang Su Ying Ding Wu Li Rong Xue Wu Hong Li Zhang Yan Mei Zhang Shao Ming Yan Lu Zhang ~1Department of Infectious Diseases,The First Affiliated Hospital of Kunming Medical College,Kunming 650032,Yunnan Province,China ~2Departrnent of Hepatology,Kunming Third Municipal People’s Hospital,Kunming 650041,Yunnan Province,China.A randomized controlled clinical trial on the treatment of Thymosin-a1 versus interferon-α in patients with hepatitis B[J].World Journal of Gastroenterology,2001,7(3):411-414. 被引量：48
